Carisma Therapeutics
  • About UsOpenClose
    • LeadershipOpenClose
    • BoardOpenClose
  • TechnologyOpenClose
    • PublicationsOpenClose
  • PipelineOpenClose
    • CT – 0508OpenClose
  • For PatientsOpenClose
  • NewsroomOpenClose
    • Media CoverageOpenClose
    • Press ReleasesOpenClose
  • Careers
  • Contact Us

In the news

Check out Carisma’s latest media coverage

Featured news

Dr. Debora Barton of CARISMA Therapeutics On The 5 Things Everyone Needs To Know About Cancer

In this interview series called, “5 Things Everyone Needs To Know About Cancer” we are talking to experts about cancer such as oncologists, researchers, and medical directors to address these questions.

Medium | October 20, 2021
News

Inside Carisma Therapeutics’ Fast Track Designation by the FDA

Carisma Therapeutics is making waves again with its recent news that it has been granted Fast Track Designation by the FDA to its CT-0508 for the treatment of patients with solid tumors.

Cell & Gene | 9.26.21
News

FDA Grants Fast Track Designation to Novel HER2-Targeted CAR-M Therapy in Solid Tumors

The FDA has granted fast track designation to the HER2-targeted chimeric antigen receptor-macrophage (CAR-M), CT-0508, for the treatment of patients with solid tumors, announced Carisma Therapeutics, Inc.

Targeted Oncology | 9.22.21
News

FDA Grants Fast Track Designation to CAR Macrophage Cell Therapy for HER2-positive Tumors

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2. CT-0508 (Carisma Therapeutics) is an autologous, gene-edited chimeric antigen receptor...

Healio | 9.22.21
Load More
  • Carisma Therapeutics
    Connect with Carisma
    • LinkedIn
    • Twittter
    • Facebook
  • About Us
    • Leadership
    • Board
  • Technology
    • Publications
  • Pipeline
    • CT – 0508
  • For Patients
  • Newsroom
    • Media Coverage
    • Press Releases
  • © Carisma Therapeutics, Inc. 2022
  • Privacy Policy